Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
214 hedge funds and large institutions have $3.24B invested in Blueprint Medicines in 2020 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 98 increasing their positions, 55 reducing their positions, and 48 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 55
24% more call options, than puts
Call options by funds: $36.3M | Put options by funds: $29.3M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.79% less ownership
Funds ownership: 103.14% → 102.35% (-0.79%)
6% less funds holding
Funds holding: 227 → 214 (-13)
20% less capital invested
Capital invested by funds: $4.06B → $3.24B (-$829M)
23% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$62.5M |
| 2 |
JP Morgan Chase
New York
|
+$55.1M |
| 3 |
Alkeon Capital Management
New York
|
+$49.9M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$49.4M |
| 5 |
CC
Casdin Capital
New York
|
+$39.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$146M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$62.2M |
| 3 |
CCM
Cadian Capital Management
New York
|
-$47.7M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$34.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$18.3M |
BPMC Hedge Fund Activity: Q1 2020 in Review
214 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2020, worth a combined $3.24B — down 20% from $4.06B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of BPMC and 37 opened new positions — a net loss of 11 holders — while 55 trimmed existing stakes and 98 added.
The largest buyer was HealthCor Management, adding an estimated $62.5M. The largest seller was Fidelity Investments, cutting an estimated $146M.
- 214 institutional investors held Blueprint Medicines (BPMC) as of Q1 2020, down from 227 in Q4 2019.
- Funds reported $3.24B of Blueprint Medicines stock for Q1 2020, down 20% quarter-over-quarter.
- 37 funds opened new Blueprint Medicines positions in Q1 2020 and 48 closed out, a net change of -11 holders.
- The largest Blueprint Medicines buyer in Q1 2020 was HealthCor Management, an estimated $62.5M added.
- The largest Blueprint Medicines seller in Q1 2020 was Fidelity Investments, an estimated $146M sold.
Based on aggregated 13F filings for Q1 2020.